This study evaluates the influence of Silymarin in reducing laboratory, ultrasonographic
(Fibroscan) and metabolic components of NAFLD. Half of the patients will receive Silymarin
(Verum) while the other half will receive placebo
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital Rijeka
Collaborators:
Belupo Belupo d.o.o., Koprivnica, Croatia University of Rijeka, Faculty of Health studies University of Rijeka, Medical Faculty